Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.25%AUDUSD-1.11%GBPCHF+1.03%AUDJPY-0.96%USDCHF+0.87%GBPCAD+0.79%EURGBP-0.70%USDCAD+0.66%CHFJPY-0.66%GBPNZD+0.63%AUDNZD-0.61%EURAUD+0.57%USDTHB+0.57%EURUSD-0.56%NZDUSD-0.51%CADJPY-0.48%AUDCAD-0.48%GBPTRY+0.41%EURJPY-0.39%NZDCHF+0.37%GBPHKD+0.32%GBPJPY+0.32%NZDJPY-0.31%EURCHF+0.30%USDTRY+0.30%GBPMXN-0.28%AUDCHF-0.27%CADCHF+0.21%USDCNH-0.20%USDJPY+0.17%USDILS+0.16%NZDCAD+0.16%GBPUSD+0.14%EURCAD+0.10%SGDJPY+0.09%AUDNOK+0.05%EURNZD-0.04%EURHKD-0.04%NZDMXN+0.04%USDCOP-0.04%AUDDKK+0.04%USDMXN+0.03%EURCNH-0.03%USDHKD+0.03%EURSGD-0.03%NZDSGD+0.03%USDDKK+0.02%AUDSGD+0.01%USDZAR-0.01%USDSGD-0.01%GBPZAR0.00%GBPSGD0.00%EURDKK0.00%CHFSGD0.00%USDSEK0.00%EURSEK0.00%CHFNOK0.00%NOKJPY0.00%USDNOK0.00%EURCZK0.00%EURPLN0.00%USDPLN0.00%PLNJPY0.00%EURZAR0.00%CHFSEK0.00%EURNOK0.00%USOIL-0.50%XPTUSD-0.44%XNGUSD+0.18%HG1-0.17%GAUUSD-0.02%XAUUSD-0.02%GAGUSD-0.02%XAGUSD-0.01%C10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD-0.08%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+0.89%ZECUSDT+1.54%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.60%XLMUSD+1.84%BCHUSDT-0.45%UNIUSD+0.08%LTCUSD+0.07%HBARUSDT+2.21%SUIUSD+1.02%TONUSD+15.77%TAOUSDT+0.06%AAVEUSD-3.53%DOTUSDT+2.62%ICPUSDT-3.15%ONDOUSDT-0.44%WLDUSDT+9.48%ARBUSDT-0.35%JUPUSDT-0.20%ATOMUSDT+1.28%INJUSDT-2.53%STXUSDT+17.06%FETUSDT+2.53%SEIUSDT+0.33%PYTHUSDT-1.89%TIAUSDT+0.16%IMXUSDT+0.97%GRTUSDT+0.06%OPUSDT+0.54%WIFUSDT+3.46%IOTAUSDT+4.36%POLUSDT-3.26%AXSUSDT+1.11%FARTCOINUSDT-0.34%EOSUSDT+4.39%DYDXUSDT+3.75%GALAUSDT+4.75%ORDIUSDT+1.00%NOTUSDT+1.55%RONINUSDT+0.06%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.25%AUDUSD-1.11%GBPCHF+1.03%AUDJPY-0.96%USDCHF+0.87%GBPCAD+0.79%EURGBP-0.70%USDCAD+0.66%CHFJPY-0.66%GBPNZD+0.63%AUDNZD-0.61%EURAUD+0.57%USDTHB+0.57%EURUSD-0.56%NZDUSD-0.51%CADJPY-0.48%AUDCAD-0.48%GBPTRY+0.41%EURJPY-0.39%NZDCHF+0.37%GBPHKD+0.32%GBPJPY+0.32%NZDJPY-0.31%EURCHF+0.30%USDTRY+0.30%GBPMXN-0.28%AUDCHF-0.27%CADCHF+0.21%USDCNH-0.20%USDJPY+0.17%USDILS+0.16%NZDCAD+0.16%GBPUSD+0.14%EURCAD+0.10%SGDJPY+0.09%AUDNOK+0.05%EURNZD-0.04%EURHKD-0.04%NZDMXN+0.04%USDCOP-0.04%AUDDKK+0.04%USDMXN+0.03%EURCNH-0.03%USDHKD+0.03%EURSGD-0.03%NZDSGD+0.03%USDDKK+0.02%AUDSGD+0.01%USDZAR-0.01%USDSGD-0.01%GBPZAR0.00%GBPSGD0.00%EURDKK0.00%CHFSGD0.00%USDSEK0.00%EURSEK0.00%CHFNOK0.00%NOKJPY0.00%USDNOK0.00%EURCZK0.00%EURPLN0.00%USDPLN0.00%PLNJPY0.00%EURZAR0.00%CHFSEK0.00%EURNOK0.00%USOIL-0.50%XPTUSD-0.44%XNGUSD+0.18%HG1-0.17%GAUUSD-0.02%XAUUSD-0.02%GAGUSD-0.02%XAGUSD-0.01%C10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD-0.08%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+0.89%ZECUSDT+1.54%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.60%XLMUSD+1.84%BCHUSDT-0.45%UNIUSD+0.08%LTCUSD+0.07%HBARUSDT+2.21%SUIUSD+1.02%TONUSD+15.77%TAOUSDT+0.06%AAVEUSD-3.53%DOTUSDT+2.62%ICPUSDT-3.15%ONDOUSDT-0.44%WLDUSDT+9.48%ARBUSDT-0.35%JUPUSDT-0.20%ATOMUSDT+1.28%INJUSDT-2.53%STXUSDT+17.06%FETUSDT+2.53%SEIUSDT+0.33%PYTHUSDT-1.89%TIAUSDT+0.16%IMXUSDT+0.97%GRTUSDT+0.06%OPUSDT+0.54%WIFUSDT+3.46%IOTAUSDT+4.36%POLUSDT-3.26%AXSUSDT+1.11%FARTCOINUSDT-0.34%EOSUSDT+4.39%DYDXUSDT+3.75%GALAUSDT+4.75%ORDIUSDT+1.00%NOTUSDT+1.55%RONINUSDT+0.06%
EX

Exelixis, Inc. (EXEL)

NASDAQ • Healthcare

$58.41
-$0.24 (-0.4%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$59.2
Day Range$58.4 - $61.14
Avg. Volume (3M)2.2M
Market Cap$14.6B
P/E Ratio17.8
52 Week Range
$33.76$61.14
Next EarningsIn 33 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$628.6M100%
Gross Profitminus cost of goods$608M97%
Operating Incomeminus R&D and overhead$248.4M40%
Net Incomeminus taxes and the rest$212M34%

In plain terms: out of every $100 in revenue, Exelixis, Inc. keeps $34 as net profit.

Fundamentals & Financials

Revenue (TTM)
$2.4B
Net Income (TTM)
$860.6M
EPS (TTM)
$3.29
ROA (TTM)
34.5%
Current Ratio
3.46

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+22.1%Q1 2026$0.94
+13.7%Q2 2026$0.87
+6.7%Q3 2026$0.91
Next

Nov 3

in 33 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +6.7%

Exelixis topped adjusted EPS expectations but revenue missed in the second fiscal quarter of 2026, reported Aug. 5, as adjusted EPS of $0.91 beat the $0.85 estimate by 6.7% while revenue of about $628.7 million fell short of the $636.4 million consensus by 1.2%. Revenue rose 10.6% from $568.3 million a year ago, with gross margin near 96.7% and operating margin around 39.5% as gross profit came to about $608.0 million and operating income reached roughly $248.4 million. Net income increased 14.7% to about $212.1 million from $184.8 million a year earlier, and operating cash flow totaled $559.6 million. The U.S. remained the main revenue contributor at about $578.4 million, Europe climbed 24.2% to roughly $46.0 million, and Japan declined 33.1% to about $4.3 million.

View full earnings history

About Exelixis, Inc.

Exelixis, Inc. is a NASDAQ-listed biotechnology company that develops and commercializes cancer medicines and other therapies, generating $2.3 billion in FY2025 revenue. Its marketed portfolio centers on CABOMETYX tablets, COMETRIQ capsules, and COTELLIC for oncology, alongside MINNEBRO for hypertension, with commercial activity in the United States and Japan.

Name
Exelixis, Inc.
CEO
Michael Morrissey
Website
www.exelixis.com
Industry
Healthcare
Year Founded
1994
Employees
1,077

Today's Snapshot

AI-generated

EXEL closed slightly lower at 58.41, while its sector was weaker. Shares changed hands at about a quarter more than its usual level.

Trading Volume

Above 10d avg 2.3M

3M

vs S&P 500 Today

Underperforming Market

-0.60%

Updated: September 30, 2026 at 20:27 UTC

Technical Indicators

5 Buy3 Neutral0 Sell
EXEL is about 58.41 with short- and medium-term averages trading below current price and the 200-day average also well underfoot, giving a constructive moving-average alignment while ADX shows only a weak trend. Momentum indicators and CCI are positive, suggesting near-term buying interest, but MACD and oscillators are more neutral and on-balance volume is not confirming strength. Volatility remains modest, and the classic pivot aligns very near the current level, offering a reference point for intraday balance. Technical takeaway: Buy — positive momentum and supportive moving averages contrast with a weak overall trend and mixed volume confirmation.
All signals
  • EMA (5 indicators)$49.45 - $57.99
    Buy
  • RSI (14)56.65
    Neutral
  • Stochastic %K (14, 3, 3)76.92
    Neutral
  • MACD Level (12, 26)0.75
    Neutral

Peers & Related Assets

MRNAModerna, Inc.
$192.57-5.3%
RVMDRevolution Medicines, Inc.
$205.26+0.4%
HALOHalozyme Therapeutics, Inc.
$110.4-1.0%
BBIOBridgeBio Pharma, Inc.
$65.8-0.3%
MDGLMadrigal Pharmaceuticals, Inc.
$503.96-1.1%
BMRNBioMarin Pharmaceutical Inc.
$60+0.2%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.